MiNK Therapeutics, Inc (INKT) insider trading

Every open-market stock purchase and sale by MiNK Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • Insiders sold $38.8K over the last 12 months (3 sales). No open-market buys.
  • Last insider buy: Agenus Inc (Insider), $472, 2 years ago.

Last 12 months: insiders bought $0 (0 buys) and sold $38.8K (3 sales). Last close $11.87 on Jun 4, 2026.

Recent INKT insider trades

DateInsiderTradeValue
Jun 4, 2026Barbara Ryan (Insider)Sold$12.8K
Jun 4, 2026Barbara Ryan (Insider)Sold$6.3K
Jun 1, 2026Brian Corvese (Insider)Bought (not open market)$17.9K
Jun 1, 2026Barbara Ryan (Insider)Bought (not open market)$17.8K
Jun 1, 2026Peter Behner (Insider)Bought (not open market)$16.3K
Jun 1, 2026Ulf Wiinberg (Insider)Bought (not open market)$14K
Jun 1, 2026John Bradley Holcomb (Insider)Bought (not open market)$13.5K
Mar 10, 2026Barbara Ryan (Insider)Sold$7.7K
Mar 10, 2026Barbara Ryan (Insider)Sold$4.6K
Mar 9, 2026Barbara Ryan (Insider)Sold$2K
Mar 2, 2026Brian Corvese (Insider)Bought (not open market)$17.9K
Mar 2, 2026Barbara Ryan (Insider)Bought (not open market)$17.8K
Mar 2, 2026Peter Behner (Insider)Bought (not open market)$16.3K
Mar 2, 2026Ulf Wiinberg (Insider)Bought (not open market)$14K
Mar 2, 2026John Bradley Holcomb (Insider)Bought (not open market)$13.5K
Mar 2, 2026Barbara Ryan (Insider)Sold$1.1K
Feb 27, 2026Barbara Ryan (Insider)Sold$4.3K
Jan 2, 2026Jennifer Buell (CEO)Bought (not open market)$350K
Jan 2, 2026Jennifer Buell (CEO)Sold (not open market)$111K
Jan 2, 2026Jennifer Buell (CEO)Bought (not open market)—
Jan 2, 2026Ulf Wiinberg (Insider)Bought (not open market)—
Jan 2, 2026Peter Behner (Insider)Bought (not open market)—
Jan 2, 2026Barbara Ryan (Insider)Bought (not open market)—
Jan 2, 2026Brian Corvese (Insider)Bought (not open market)—
Dec 1, 2025Brian Corvese (Insider)Bought (not open market)$17.9K

Who's trading INKT

Get free alerts when an insider at MiNK Therapeutics, Inc files a new trade →